V entricular fibrillation (VF) is a life-threatening arrhythmia that often occurs in patients with ischemic heart disease (IHD). The Purkinje system has been reported to play a pivotal role in triggering and perpetuating VF, 1 and catheter ablation targeting Purkinje potentials can suppress this arrhythmia.
Purkinje SMVT Conversion After VF Ablation and an urgent ablation was then performed. We obtained written informed consent for VF ablation from each patient and their family. Antiarrhythmic drugs were continued in almost all cases during the ablation.
Mapping and Ablation
Multielectrode catheters and an ablation catheter were introduced percutaneously, and a 3-dimensional (3D) mapping system (CARTO; Biosense Webster, Diamond Bar, CA or EnSite NavX; St. Jude Medical, St Paul, MN) was used in all patients. A 3D voltage map of the left ventricle was constructed before ablation, and the size of low-voltage areas was measured. However, this step was completed for only 8 patients, as the rest of the patients exhibited hemodynamic instability or an older version of the 3D mapping system was used, which lacked the functionality to calculate the lowvoltage area. We defined regions with an electrogram voltage <1.5 mV as low-voltage areas. VF was triggered by the same ventricular premature contraction (VPC) in each patient, and the origin was identified by determining the earliest activation and pace mapping. A Purkinje potential, a sharp and high-frequency deflection, always preceded the onset of the trigger VPC, and its localization was carefully mapped. The earliest Purkinje potential during the trigger VPC was targeted for ablation. If monomorphic VT was induced and was hemodynamically stable, entrainment and activation mapping using the 3D mapping system were performed to determine the mechanism and circuit of the VT. Among the induced VTs, we defined those with the involvement of a bundle branch, fascicle, or distal Purkinje network in the VT circuit as Purkinje-related VTs, 10 and those with the critical isthmus in the low-voltage area and lacking the involvement of the Purkinje system as scar-related VTs. Ablation was performed with a maximum power of up to 50 W and a target temperature of 42°C for the irrigation catheter and 58 °C for the nonirrigated 4-mmor 8-mm-tip catheter.
The end point of the ablation was the elimination of VF and VT. With the exception of 3 patients with hemodynamic instability (patients no. 2, 17, and 20), we confirmed the noninducibility of VF and VT by an isoproterenol infusion and electric stimulation from the right ventricle and left ventricle in all patients at the end of the session.
Follow-Up
The patients were followed up in the outpatient clinic every 1 to 2 months and in the device clinic every 6 months after the ablation; symptoms, electrocardiograms, and implantable cardioverter defibrillator (ICD) interrogation logs were checked at every visit. An ICD was implanted in 17 of 21 patients before or after the ablation. Three patients refused an ICD, and implantation was avoided in 1 patient because of their high risk of skin infection. Clinical success was defined as no recurrence of any sustained VT or VF during the follow-up period. Fifteen of 21 patients continued to take class III antiarrhythmic drugs after the ablation. If an arrhythmia recurred, a change in medication, reprogramming of the ICD parameters, and reablation were considered.
Statistical Analysis
Categorical variables were expressed as numbers and percentages. Continuous variables were expressed as mean±SD or median with 25% to 75% interquartile range. The variables were compared using the Students t test or Fisher exact test. The threshold for statistical significance was P<0.05.
Results

Patient Characteristics
Patient characteristics are summarized in Table 1 . The mean age was 66±12 years, and 91% of the patients were men. The rates of comorbid diabetes mellitus, hypertension, and chronic kidney disease were relatively high: 57%, 67%, and 62%, respectively. Sixteen patients had already undergone complete revascularization before the occurrence of VF. The interval from the onset of an infarction to VF occurrence was 1 to 59 days (median, 7 days) in 14 patients with acute or subacute myocardial infarction (MI) and 1.4 to 20 years (median, 9.5 years) in 6 patients with remote MI. Among 14 patients with acute or subacute MI, 5 had undergone coronary revascularization after VF events. The other 9 had experienced VF at an interval of 1 to 8 days (median, 3 days) after revascularization.
The patients in this study were divided into 2 groups: 14 patients who only had VF before ablation and 7 patients who had both VF and concomitant monomorphic VT before ablation. Monomorphic VT was sustained in all cases. The 2 groups demonstrated no significant differences in patient characteristics except for total radiofrequency time. The patients with both VF and monomorphic VT had significantly longer total radiofrequency time.
VF and nonsustained polymorphic VT were repeatedly initiated by the trigger VPC with the same QRS morphology in all patients. The morphology of the VPC was a right bundle branch block configuration with a superior axis in 15 patients, an right bundle branch block configuration with an inferior axis in 5 patients, and an atypical left bundle branch block configuration with a superior axis in 1 patient. The mean number of failed antiarrhythmic drugs was 2.9±1.2, corresponding to 62%, 62%, 95%, and 19% failed antiarrhythmic drugs with class IB, class II, class III, and class IV (verapamil), respectively. Nine patients required mechanical support such as an intra-aortic balloon pump (patients no. 9, 12, 13, 15, 16, 17, 19, 20 , and 21) and extracorporeal membrane oxygenation (patients no. 13, 15, and 20) to assist their hemodynamic state.
Mapping and Ablation
The site of the target VPC was located in the left ventricular septum in 18 patients, and in the anterolateral area in 3
WHAT IS KNOWN
• The Purkinje system plays a pivotal role in triggering and perpetuating ventricular fibrillation in patients with ischemic heart disease.
• Catheter ablation targeting Purkinje potentials can be an effective therapy for recurrent polymorphic ventricular fibrillation initiated by a triggering PVC.
WHAT THE STUDY ADDS
• In this series over a fifth of patients who had catheter ablation for recurrent ventricular fibrillation associated with ischemic heart disease subsequently had new sustained monomorphic ventricular tachycardia, and the majority were also successfully suppressed by ablation of a part of the Purkinje network located in the same low-voltage area as the site of the ablation for ventricular fibrillation.
• The mechanism of conversion to monomorphic ventricular tachycardia is suggested to be reentry circuit reorganization because of the creation of a unidirectional block and conduction delay by ablation within the Purkinje network. 
Conversion of VF to New Monomorphic VT
The therapies used in this study cohort are outlined in the flowchart (Figure 1) . Among the 21 patients with primary VF, 14 had only VF before the ablation. In these 14 patient, the first ablation for VF was performed successfully, and the noninducibility of any ventricular arrhythmias was confirmed by programmed stimulation at the end of the session. After this first session of ablation, total elimination of VF was achieved during the follow-up period in 6 of the 14 patients who had only VF (and no monomorphic VT) before ablation. New occurrence of monomorphic VTs after the first ablation was seen in 4 patients (29% of patients who had only VF before ablation), whereas VF recurred in 4 patients. The interval of time between ablation and the occurrence of the new VT ranged from 4 hours to 29 days (median, 4 days; Table 2 ). These new monomorphic VTs were successfully suppressed by a second ablation session in all 4 patients. Two patients with recurrent VF underwent a second ablation, which achieved acute suppression of the VF; however, in both of these patients, VF recurred even after the second ablation session. The other 2 patients with recurrent VF received only medical therapies and did not undergo reablation because the electrical storm subsided.
Concurrence of Monomorphic VT Before VF Ablation
Seven patients demonstrated concurrent monomorphic VT before the ablation (Figure 1) . In 2 of them, both VT and VF were successfully eliminated after the first ablation session. Of the remaining 5 patients, both VF and VT recurred in 2 patients, and VF alone recurred in 3 patients. Two patients with VF and VT recurrence, and 1 patient with only VF recurrence underwent a second ablation, which achieved complete 
Mechanism of Monomorphic VTs
Monomorphic VTs were documented in 11 patients: newly emergent monomorphic VT after the first ablation for VF was noted in 4 patients, and concomitant monomorphic VTs before ablation in 7 ( Table 3) . Three of 4 patients with new monomorphic VTs had Purkinje-related VTs: an interfascicular VT in 1 case (patient no. 3) and Purkinje VTs arising from the left distal Purkinje network in 2 cases (patients no. 4 and 13). The other VT (in patient no. 18) was scar-related and unrelated to the Purkinje system. All 7 cases of concomitant monomorphic VT before the ablation were Purkinje-related VTs. All 10 Purkinje-related VTs (ie, previously present and newly developed) represented cases of fast VT (mean cycle length [CL], 286±53 ms) and were unmappable because of hemodynamic compromise; nonetheless, all were successfully ablated, guided by pace-mapping, at the site where Purkinje potentials were recorded during sinus rhythm. Figure 2 shows an example of the conversion of VF into sustained monomorphic VT after VF ablation (patient no. 4). During a VF storm, 2 types of VPC were present (Figure 2A) . Both VPCs had an right bundle branch block configuration with a superior axis. Although VPC2 was always isolated, VPC1 exclusively induced VF or nonsustained polymorphic VT. The ventricular tachyarrhythmia was always polymorphic VT or VF, and monomorphic VT was not observed. The trigger VPC1 was successfully eliminated by ablation at the scar border zone with preceding Purkinje potentials ( Figure 2C ). One month after the VF ablation, an ICD intervention for the VF zone occurred. ECG monitoring and ICD interrogation revealed that a rapid sustained monomorphic VT (CL, 240 ms) was initiated by VPC2 and terminated by the ICD shock ( Figure 2B ). The QRS configurations of the monomorphic VT and VPC2 were similar. This rapid monomorphic VT was successfully ablated at a single site with a diastolic Purkinje potential during the VT, and this site was located within the same low-voltage area as the Purkinje network responsible for the VF that was successfully ablated in the first session ( Figure 2C ). After the ablation, the VT became noninducible, and VPC2 was also abolished.
Conversion from VF to Purkinje-related monomorphic VT sometimes occurred after a short interval from the VF ablation. Figures 3 through 5 show an example of the conversion from VF to monomorphic VT shortly after the VF ablation (patient no. 13 ). An urgent ablation was performed for a primary VF storm ( Figure 3A) ; however, it resulted in a recurrent electrical storm of a newly emergent monomorphic VT 4 hours after the first ablation session ( Figure 3B ). On the following day, a second urgent ablation was performed. The target VPC had an right bundle branch block configuration with an inferior axis and was similar to the QRS configuration during monomorphic VT. In the second session, sustained monomorphic VT, not VF, was repeatedly induced by the VPC. Diastolic Purkinje potentials were recorded from the left ventricular midseptum during the VPC that preceded the onset of the QRS by 150 ms ( Figure 4A ). The coupling interval from the prior conducted QRS in sinus rhythm to the trigger Purkinje potential was 320 ms. A diastolic Purkinje potential was also recorded during the monomorphic VT. From this site, sustained monomorphic VT was reproducibly induced by a single stimulus with the same coupling interval ( Figure 4B ). Pacing from this site terminated the VT without global capture ( Figure 5 ). After the radiofrequency energy application to this site, which was in the same low-voltage area as the sites of the first successful ablation, the VT became noninducible (Figure 6 ), and the trigger VPC was eliminated.
Long-Term Follow-Up After Ablation
Bailout from a VF/VT storm was successfully achieved in 1 or 2 procedures (mean, 1.4±0.5 procedures) in all patients. There were no VF storms after the ablation during the median follow-up of 28 months (interquartile range, 16-68 months). Patient no. 2 died from heart failure 1 month after the procedure and was excluded from the calculation of follow-up periods because of insufficient follow-up data.
Six patients (29% of the total) experienced arrhythmia recurrences. In 4 cases (patients no. 12, 15, 16, and 20), 1 to 3 episodes of VF occurred within 5 days after the ablation and resolved spontaneously with medical therapy alone. In the other 2 patients (patients no. 6 and 14), VF recurred at 25 and 35 months, respectively. These patients received additional medical therapies and no subsequent ICD intervention. During the follow-up period, 10 patients died: 3 from heart failure, 2 from stroke, 2 from sepsis, 2 from cancer, and 1 from pneumonia. There were no deaths from arrhythmia.
Discussion
Previous investigators reported that ablation targeting Purkinje potentials could suppress VF in ischemic cardiomyopathy. [2] [3] [4] [5] [6] [7] [8] [9] Compared with previous studies, the present study has reviewed data regarding more cases of VF ablation in patients with IHD, and collected over a longer follow-up period. To our knowledge, no previous study has analyzed the conversion of VF into monomorphic VT by catheter ablation.
Monomorphic VT Including Purkinje Fibers in the Circuit
Three of 4 newly emergent monomorphic VTs seen after VF ablation were Purkinje-related VTs, as were all 7 concomitant monomorphic VTs before VF ablation. In all patients, the diagnosis of these Purkinje-related monomorphic VTs was determined by mid-diastolic Purkinje potentials, not by entrainment pacing. These monomorphic VTs included the Purkinje system in part of the circuit and were successfully suppressed by ablation with guidance of Purkinje potentials Conversion from ventricular fibrillation (VF) to rapid sustained monomorphic ventricular tachycardia (VT) shortly after the VF ablation (patient no. 13). A, Twelve-lead ECG during the first ablation session. VF was initiated by the trigger ventricular premature contraction (VPC). B, Twelve-lead ECG during the second ablation session, which was performed the next day. Sustained monomorphic ventricular tachycardia (SMVT; cycle length [CL], 280 ms) was initiated by the trigger VPC. Purkinje SMVT Conversion After VF Ablation during sinus rhythm and pace mapping. Therefore, they were diagnosed as Purkinje-related VTs.
This study included a relatively small number of scarrelated VTs. We speculate that there are 2 possible reasons. First, the majority of patients had acute or subacute MI, and different arrhythmic substrates might be involved with remote MI. That is, compared with the scar-related isthmus, the Purkinje network had greater involvement in the establishment of the VT circuit. Purkinje fibers are relatively resistant to ischemia. 11 Second, 95% of patients had already taken class III antiarrhythmic drugs before ablation, which might have suppressed the circuit of the scar-related VT in these patients. Although Purkinje firing with a coupling interval of 320 ms (arrow) conducted to the ventricular muscle and produced the VPC, the firing with a shorter coupling interval (270 ms) did not conduct to the ventricular muscle (arrowhead). A diastolic Purkinje potential was recorded during VT. B, A single stimulus (S) from this site with a coupling interval of 320 ms repeatedly induced sustained monomorphic VT. Purkinje SMVT Conversion After VF Ablation Focal tachycardia and macrore-entry have been reported as mechanisms of Purkinje-related VT. 12, 13 Because the Purkinjerelated VTs in this study were fast (mean CL, 286±53 ms), a detailed electrophysiological study was difficult to perform. However, we could detect a re-entrant mechanism in some patients (eg, in patient no. 14).
Bogun et al 13 reported that VTs that included Purkinje fibers as part of the re-entry circuit in patients with a MI exhibited a narrow QRS configuration of less than 145 ms. However, the mean QRS duration of the Purkinje-related VT in this study was wider (184±17 ms). We speculate that one of the reasons for the wider QRS is the shorter VT-CL observed in this study. Although the mean VT-CL in the study by Bogun et al 13 was 402±82 ms, the VT-CL in the present study was 286±53 ms.
Conversion to Monomorphic VT After VF Ablation
In 4 of 14 patients with only VF before ablation, conversion to Purkinje-related monomorphic VT was observed; monomorphic VT, which was never observed before the VF ablation in these patients based on their records from ICD interrogation or stay in the intensive care department, became dominant after the VF ablation. Tsuchiya et al 14 reported the case of a patient who exhibited a transition from idiopathic Purkinje-related polymorphic VT to monomorphic VT after the administration of class IC drugs; however, to the best of our knowledge, the present study is the first retrospective evaluation of conversion to Purkinjerelated monomorphic VT by the ablation of ischemic VF.
Although the hypotheses of mother rotors, multiple wavelets, and focal sources [15] [16] [17] have been advocated as mechanisms of VF, there is no single hypothesis explaining the maintenance of VF. In any case, it is clear that the Purkinje network is closely related to the trigger and maintenance of VF. 3, 18, 19 As a possible mechanism of VT conversion, we speculate that creating a unidirectional conduction block or conduction delay within the Purkinje network by ablation organized the unstable re-entry circuit into a stable one, which caused a newly emergent monomorphic VT. Hayase et al 20 reported that the localization of the VF rotor was consistent with the critical isthmus of the monomorphic VT. The VT and VF originated from nearby regions, which may have created a condition whereby the ablation easily modified the arrhythmic substrates. In fact, 3 of 4 patients with new monomorphic VT in this study had Purkinje-related VTs, and the circuits of these VTs were located within the same low-voltage area, and likely within the same Purkinje network, as the circuits responsible for the VF that was ablated during the 1st session. It is important to recognize the existence of Purkinje-related VT because the ablation strategy for Purkinje-related VT might differ from that of scar-related VT. That is, the strategy of ablation for Purkinje-related VT is simply to identify and ablate the Purkinje potential, which was often located near the VF ablation site. However, electroanatomical mapping of the entire affected region is often required in the ablation of scarrelated VT, and all of the possible critical isthmuses must be eliminated within the wide scar areas. The efficacy of VF storm ablation 6, 21 and urgent ablation for ventricular arrhythmias during acute heart failure 22 has already been reported. In this study, VF recurrence was present in 6 patients; however, the electrical storms had subsided and all the recurrent arrhythmias were controlled by medical therapy alone. The results of our study seem to be comparable to those of previous reports. 5, 6, 21, 22 
Study Limitations
This study included a relatively small cohort of patients. It is unclear whether concomitant monomorphic VT was absent before the VF ablation in patients without ICDs. However, all patients with VF storms were monitored in the intensive care unit, and no monomorphic VTs were observed. Therefore, we think that these 4 patients had newly emergent monomorphic VTs after the VF ablation. It is noteworthy that there was no VF recurrence concomitant with the newly emergent monomorphic VT after the VF ablation.
Conclusion
VF ablation in patients with IHD was feasible and effective as a bailout therapy for electrical storm, and resulted in a good outcome in the majority of patients. However, over one fifth of patients included in this study, who did not have monomorphic VT before ablation, developed Purkinje-related monomorphic VT after the VF ablation. These newly emergent VTs were related to the same Purkinje network that had been successfully ablated in the first session to resolve VF and were also successfully suppressed by ablation of the Purkinje system in the second session. Although VF ablation in IHD seems to have a high success rate in general, the possibility of conversion from VF to Purkinje-related monomorphic VT, and the existence of new VT circuits in the same Purkinje network at the initial VF ablation site should always be kept in mind.
